Aerpio Therapeutics, Inc.

Eyepoint Pharmaceuticals, Inc.

Aerpio Pharmaceuticals, Inc.

Aeripo Therapeutics Inc.

Akebia Therapeutics, Inc.

Kevin Gene Peters

Robert A Shalwitz

Michael Allen Flynn

John M Janusz

Michael Glenn Davis

Rocco Jamie Rotello

Alexander Smith

James Densmore Copp

Michael Glen Davis

James Copp

The disclosure provides compositions comprising multi-specific compounds, including a compound that targets a phosphatase and a receptor tyrosine kinase agonist. Also provided are methods for the treatment of conditions associated with angiogenesis, comprising administering a multi-specific compound that targets a phosphatase and a receptor tyrosine kinase agonist.

Method of treating an ocular condition by administering multispecific antibodies that activates TIE2 and binds a receptor tyrosine kinase agonist

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions associated with angiogenesis, for example, intraocular pressure, ocular hypertension, and glaucoma.

Methods of treating intraocular pressure with activators of Tie-2

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.

Compositions, formulations and methods for treating ocular diseases

The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.

Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta)

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions, for example, intraocular pressure, ocular hypertension, and glaucoma.

Tie-2 activators targeting the Schlemm's canal

Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.

Methods for treating vascular leak syndrome and cancer

Method of treating ocular conditions by administering an antibody that activates Tie2 and binds VEGF

Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTP&#x3b2;), and uses thereof.

Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP&#x3b2;. Further disclosed are formulations to increase the efficacy of the compounds that activate Tie-2 and inhibit HPTP&#x3b2;.

Growing community of inventors

Cincinnati, OH, United States of America

Kevin Gene Peters